ANXA11 and proteostasis deficiencies: When considering the 3–6% of TDP-43 proteinopathy cases with annexin A11 aggregates (i.e., cases without FTLD–TDP Type C and without a pathogenic ANXA11 variant), there is a suggestion that increased proteostatic burden or genetics may be involved.